Este trabalho teve como objetivo conhecer como se dão as interações familiares de adolescentes com diabetes tipo 1 desde o diagnóstico da doença.Utilizou-se como referencial metodológico a História Oral .Os dados coletados mediante entrevistas gravadas com sete adolescentes foram analisados à luz do Modelo Calgary para Avaliação da Família de Wright e Leahey.As narrativas demonstraram que apesar do acréscimo de atividades na rotina diária do adolescente e da família, relacionadas à manutenção e controle do diabetes, as interações familiares sofrem poucas modificações com a chegada da doença e que os conflitos entre os pais e o adolescente com diabetes não diferem tanto daqueles ocorridos entre os pais e adolescentes saudáveis.A superproteção foi um sentimento percebido pelos adolescentes após o surgimento da doença,pois os pais têm preocupações com complicações imediatas e em longo prazo. O principal vínculo demonstrado pelos adolescentes entrevistados com a suas famílias foi o vínculo de confiança. Para eles é muito importante saber que conquistaram a confiança de seus pais de que podem ter certa autonomia em relação ao manejo do diabetes.Com os irmãos compartilham superficialmente o diabetes,mesmo aqueles que mantêm relações mais estreitas.A família extensa também oferece contribuições em diferentes fases da doença. Os adolescentes entrevistados forneceram dados de que sua comunicação verbal com sua família é ampla e direta. Sentem-se livres e confiantes em falar abertamente sobre assuntos diversos com os pais e os outros membros que coabitam, relatando também com quem se relacionam melhor em casa. Percebe-se também que a família tenta de alguma maneira moldar-se de acordo com as necessidades da pessoa que tem diabetes,na organização e funcionamento.Sentimentos de gratidão são demonstrados pela associação especializada em educação em diabetes, citada como a responsável por todo ou grande parte do conhecimento adquirido,principalmente pelas atividades oferecidas no acampamento para jovens, e também como fonte de solução de problemas oriundos do diagnóstico do diabetes para os pais e para os próprios adolescentes. / This study aimed to understand how to give the family interactions of adolescents with type 1 diabetes since diagnosis of illness. The method used was Oral History y. Data collected through recorded interviews with seven adolescents were examined in the light of Wright e Leaheys Calgary Family Evaluation Model .Narratives demonstrated that despite the increased activities in the daily routine of the adolescent and family for care and control of diabetes, family interactions experience little change with the arrival of the illness and that conflicts between parents and adolescents with diabetes do not differ from those that occurred between parents and healthy adolescents. Overprotection was a sentiment felt by the teenagers after the onset of the disease because parents have concerns about immediate complications and long term. The main bond shown by the adolescents interviewed with their families was the bond of trust. Adolescents share the diabetes management with brothers superficially, even those who maintain more closed. Extended family also offers contributions in different stages of the disease. The adolescents interviewed communicate with your family is extensive and direct, feeling confident to talk about various issues with parents and other members, also reporting to whom they relate better at home. Family tries shape up according to the needs of the person who has diabetes, the organization and function.

Lam, Kwok Lim. / "October 2010." / Thesis (Ph.D.)--Chinese University of Hong Kong, 2011. / Includes bibliographical references (leaves 142-173). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract also in Chinese.

在2型糖尿病病人身上，常常併發高膽固醇血症，HMG CoA 還原酶的抑制劑常常用作治療這類病症。由於高膽固醇血症與胰島素抵抗和2型糖尿病有著密切關係，我們推測辛伐他汀對於2型糖尿病的發展有著保護和有利的作用。在這項研究中，我們主要測試了辛伐他汀 （10 nM； 24 hr）對於胰島β細胞主要功能的影響，包括其對於葡萄糖的胰島素分泌功能影響。我們假設，在肥胖/糖尿病（db⁺/ db⁺）小鼠分離的胰島，辛伐他汀可以恢復葡萄糖 （5 mM和15 mM）引起的胰島素分泌（加上降低的胰島素含量）。 / 在這個項目中，我們運用24周大的基因糖尿糖C57BL/KSJ +db/+db (db⁺/db⁺)肥鼠和相同年齡的無糖尿病C57BL/KSJ +m/+m (db⁺/m⁺)小鼠作為動物模型。通過應用obese/diabetic (db+/db+)和lean/non-diabetic (db+/m+)中分離的胰腺胰島和胰島β細胞，我們研究了胰腺胰島功能性障礙的潛在機理以及辛伐他汀對於恢復葡萄糖 （5 mM和15 mM）引起的胰島素分泌（加上降低的胰島素含量）的有利作用。資料清晰的顯示，葡萄糖引起的胰島素分泌和胰島素含量在obese/diabetic (db+/db+)的胰腺胰島中明顯低於在lean/non-diabetic (db⁺/m⁺)的胰腺胰島中。在24hr的辛伐他汀處理後，辛伐他汀恢復了葡萄糖 （5 mM和15 mM）引起的胰島素分泌（加上降低的胰島素含量）及葡萄糖 （15 mM）引起的胞內鈣離子變化。 / 在這個項目中，我們證明鈣敏感受體 （CaSR）在obese/diabetic (db⁺/db⁺)中的表達量明顯較低，而辛伐他汀的處理可以顯著性增加鈣敏感受體在obese/diabetic (db⁺/db⁺)胰島中的表達。有人建議說，obese/diabetic (db⁺/db⁺)的胰島中被抑制的鈣敏感受體表達與胰島β細胞的胰島分泌功能障礙有關。這暗示了辛伐他汀可能通過變構啟動鈣敏感受體來恢復obese/diabetic (db⁺/db⁺)胰島中葡萄糖引起的胰島素分泌和胰島含量。實驗也同樣証明辛伐他汀調節的PLA₂信號通路對於辛伐他汀改善obese/diabetic (db⁺/db⁺)胰島β細胞的胰島素分泌功能起著至關重要的作用。除此之外，我們的實驗結果證明高濃度的葡萄糖處理顯著的增加了obese/diabetic (db⁺/db⁺)細胞膜肌動蛋白骨架的密度，而辛伐他汀顯著的減少了這一變化。因此，obese/diabetic (db⁺/db⁺)胰島β細胞的胰島素分泌障礙是由肌動蛋白細胞骨架聚集阻礙胰島素顆粒胞吐引起的。而辛伐他汀通過解聚和重組肌動蛋白細胞骨架來改善obese/diabetic (db⁺/db⁺)胰島β細胞的胰島素分泌功能。 / 在這項研究中，我們的實驗結果證明葡萄糖可以顯著提高obese/diabetic (db⁺/db⁺)胰島β細胞內ROS的含量。而辛伐他汀處理部分降低了胰島β細胞內ROS的含量。除此之外，我們還研究了5 mM和15 mM葡萄糖對於內質網應力（ER-stress）相關的蛋白比如PERK, eIF2α 和IRE1表達的影響。這些內質網跨膜蛋白可以感應ER-stress從而啟動應力感測器來開啟複雜的信號通路。與lean/non-diabetic (db⁺/m⁺)相比，PERK and eIF2α在obese/diabetic (db⁺/db⁺)的胰島中表達量更低，這表明obese/diabetic (db⁺/db⁺)胰島β細胞的功能性障礙可能與ER-stress有關。而辛伐他汀的處理明顯的增加了這些蛋白的表達量，由此證明辛伐他汀還通過對抗ER-stress來保護obese/diabetic (db⁺/db⁺)胰島β細胞。 / 總而言之，我們的資料第一次證明了辛伐他汀通過PLA₂信號通路變構啟動鈣敏感受體來保護obese/diabetic (db⁺/db⁺)胰島β細胞（比如：恢復葡萄糖引發的胰島素分泌和提高減少的胰島素含量），還通過提高obese/diabetic (db⁺/db⁺)胰島β細胞中被抑制的ER-stress相關蛋白的表達量來抵抗ER-stress帶來的損傷。 / Diabetics often have hyperlipidemia as a co-morbidity. Despite the well-documented cholesterol-lowering properties of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA) reductase inhibitors (statins) in treating hypercholesterolemia, the beneficial effects of statins consumption in T2DM treatment are confusing. In the current study, we examined the effects of the simvastatin (10 nM; 24 hr) on β-cell function leading to insulin secretory response to glucose. We hypothesized that statins restore the blunted glucose (5 mM and 15 mM)-induced insulin secretion (plus the reduced insulin content) of isolated pancreatic islets of obese/diabetic (db⁺/db⁺) mice. / In the present study, genetically diabetic C57BL/KSJ +db/+db (db⁺/db⁺) mice at 24 week of age and their age-matched non-diabetic littermates C57BL/KSJ +m/+m (db⁺/m⁺) were used. Our results clearly showed that the suppressed glucose (5 mM and 15 mM)-induced insulin release (plus insulin content) and glucose (15 mM)-induced [Ca²⁺]i changes of isolated pancreatic islets of obese/diabetic (db⁺/db⁺) was restored after simvastatin (10 nM; 24 hr) treatment. / The biochemical existence of CaR in pancreatic islets of lean/non-diabetic (db⁺/m⁺) and obese/diabetic (db⁺/db⁺) mice was confirmed. The suppressed/down-regulated expression of CaR was associated to the blunted insulin secretion in pancreatic β-cells of obese/diabetic (db⁺/db⁺) mice, and it was markedly up-regulated by simvastatin (10 nM; 24 hr). The involvement of CaR-mediated PLA₂ signaling in simvastatin (10 nM; 24 hr)-induced restoration of glucose (15 mM)-induced insulin secretion in pancreatic β-cells of obese/diabetic (db⁺/db⁺) mice was investigated. Our results also showed that the increased density of plasma membrane actin cytoskeleton of obese/diabetic (db⁺/db⁺) mice was significantly decreased by simvastatin (10 nM; 24 hr) treatment. The simvastatin-induced depolymerization and remodeling of actin cytoskeleton may improve insulin secretion capability in pancreatic β-cells of obese/diabetic (db⁺/db⁺) mice. / The glucose (15 mM)-induced intracellular ROS level was significantly higher in pancreatic β-cells of obese/diabetic (db⁺/db⁺) mice. The elevated ROS level was partially diminished by simvastatin (10 nM; 24 hr) treatment. The protein expressions of PERK and eIF2α (ER stress proteins) were lower in pancreatic islet cells isolated from obese/diabetic (db⁺/db⁺) mice, suggesting that abnormal expresstion/activity of PERK and eIF2α would be coupled to the ER-stress mediated failure of pancreatic β-cells of obese/diabetic (db⁺/db⁺) mice. As simvastatin (10 nM; 24 hr) up-regulated the protein expression of these proteins, this drug exerted protective effect on pancreatic β-cells against ER stress and restored the blunted glucose (15 mM)-induced insulin secretion (plus the reduced insulin content) in obese/diabetic (db⁺/db⁺) mice. / In conclusion, our results demonstrate, for the first time, that simvasatatin (a HMG-CoA reductase inhibitor) (10 nM; 24 hr) provides beneficial effects (i.e. restoration of the blunted glucose-induced insulin release plus the reduced insulin content) in pancreatic β-cells of obese/diabetic (db⁺/db⁺) mice via the allosteric modification/up-regulation of extracellular calcium-sensing receptor through the PLA₂ signaling pathway, and provides protective/antioxidant effects against oxidative stress caused by chronic hyperglycemia in pancreatic β-cells of obese/diabetic (db⁺/db⁺) mice by up-regulating protein expression of the suppressed ER stress sensors and antioxidant enzyme. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Au, Lai Shan. / Thesis (Ph.D.) Chinese University of Hong Kong, 2013. / Includes bibliographical references (leaves 458-532). / Abstracts also in Chinese.

alpha-Glucosidase from yeast was used to screen for alpha-glucosidase inhibitory activities in Chinese herbal medicines. Seventy crude extracts were studied. The extracts of Semen Fagopyri Esculenti, Herba Euphorbiae Humifusae, Radix Polygoni Multiflori, Cortex Cinnamomi, Radix Paeoniae Rubra, and Radix Paeoniae Alba exhibited alpha-glucosidase inhibitory activities. These herbs have high potential for finding active compounds to develop into new antidiabetic drugs. / In this study, an assay technique involving brush border membrane vesicles was developed to screen for glucose uptake inhibitory actions in sixteen compounds from natural sources. Two compounds, namely naringenin and desoxyrhaponticin, were demonstrated to exhibit moderate inhibitory action on glucose uptake in rabbit intestinal brush border membrane vesicles, and showed very strong inhibitory action in rat everted intestinal sleeves. The kinetics study indicated that they behave as competitive inhibitors on glucose uptake. Moreover, they could reduce the level of the glucose uptake in the diabetic rat intestinal and renal membrane vesicles. In vivo study further demonstrated that desoxyrhaponticin could significantly reduce the glucose levels after a single oral administration of glucose in neonatal streptozotocin-induced diabetic rats, but not naringenin. These results suggest that naringenin and desoxyrhaponticin may be useful in the control of hyperglycemia. They act by inhibiting glucose uptake in the intestine and glucose reabsorption in the renal proximal tubules. / On the other hand, several synthetic compounds based on the structure of valienamine were found to show strong inhibition on intestinal alpha-glucosidases such as sucrase, glucoamylase and maltase. The strongest inhibitor was further studied. It could reduce the postprandial plasma glucose level of neonatal streptozotocin-induced diabetic rats. These results demonstrated that it has the potential to develop inter an oral antihyperglycemic agent. / The objective of this study is to improve the postprandial hyperglycemic conditions of diabetes by two approaches: (1) inhibiting the digestive enzymes (alpha-glucosidases), and (2) inhibiting active glucose transport in the small intestine. We have screened for new inhibitors of alpha-glucosidase and monosaccharide cotransporters from natural products and their derivatives. These compounds may be useful in the management of type 2 diabetes and diabetic complications. / Type 2 diabetes mellitus accounts for 90-95% of all diabetic cases and has become a major health concern over the world. There is increasing evidence that postprandial hyperglycemia, a hallmark of diabetes, plays a critical role in the development of type 2 diabetes and cardiovascular complications. Therefore the early identification of postprandial hyperglycemia and its effective control can offer the potential for early intervention and prevention of diabetic complications. / Li Jianmei. / "August 2006." / Adviser: Christopher H. K. Cheng. / Source: Dissertation Abstracts International, Volume: 68-03, Section: B, page: 1592. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2006. / Includes bibliographical references (p. 161-180). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Electronic reproduction. [Ann Arbor, MI] : ProQuest Information and Learning, [200-] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstracts in English and Chinese. / School code: 1307.

Ho Sin Ka Janice. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2008. / Includes bibliographical references (leaves 105-119). / Abstracts in English and Chinese. / Chapter CHAPTER 1. --- Introduction / Chapter 1.1. --- Epidemiology of Type 2 Diabetes --- p.1 / Chapter 1.2. --- Risk factors contributing to Type 2 Diabetes --- p.3 / Chapter 1.2.1. --- Environmental and physiological factors --- p.3 / Chapter 1.2.2. --- Genetic factors --- p.3 / Chapter 1.3. --- Disruption of energy homeostasis in the pathogenesis of type 2 diabetes --- p.6 / Chapter 1.3.1. --- Clinical spectrum of diabetes --- p.6 / Chapter 1.3.2. --- Insulin as a key regulator of energy homeostasis --- p.7 / Chapter 1.3.3. --- Insulin secretion and glucose metabolism --- p.8 / Chapter 1.3.4. --- Insulin action and lipid metabolism --- p.9 / Chapter 1.3.5. --- Lipotoxicity and glucotoxicity --- p.12 / Chapter 1.3.6. --- Role of transcription factors as metabolic switch --- p.13 / Chapter 1.4. --- Candidate genes implicated in type 2 diabetes susceptibility --- p.15 / Chapter 1.4.1. --- Candidate genes involved in insulin secretion pathway --- p.15 / Chapter 1.4.1.1. --- HNF4A --- p.15 / Chapter 1.4.1.2. --- HNF1A --- p.16 / Chapter 1.4.1.3. --- PDX1/PBX1 --- p.17 / Chapter 1.4.1.4. --- NEUROD1 --- p.17 / Chapter 1.4.1.5. --- GCK --- p.17 / Chapter 1.4.1.6. --- KCNJ11/ABCC8 --- p.18 / Chapter 1.4.2 --- Candidate genes involved in insulin action pathway --- p.19 / Chapter 1.4.2.1. --- PPARG --- p.19 / Chapter 1.4.2.2. --- PPARA --- p.20 / Chapter 1.4.2.3. --- PPARGC1A --- p.20 / Chapter 1.4.2.4. --- ADIP0Q --- p.21 / Chapter 1.4.2.5. --- LPL --- p.21 / Chapter 1.4.2.6. --- UPC --- p.22 / Chapter 1.5. --- Hypothesis and objectives of the study --- p.23 / Chapter CHAPTER 2. --- Materials and methods / Chapter 2.1. --- Study design --- p.25 / Chapter 2.1.1. --- Two-stage candidate gene association design --- p.25 / Chapter 2.1.2. --- Power calculation --- p.27 / Chapter 2.2. --- Study cohort --- p.29 / Chapter 2.2.1. --- Subject recruitment --- p.29 / Chapter 2.2.2. --- Clinical and biochemical measurements --- p.30 / Chapter 2.2.3. --- Clinical definitions --- p.31 / Chapter 2.3. --- Genetic study --- p.32 / Chapter 2.3.1. --- Candidate gene selection --- p.32 / Chapter 2.3.2. --- SNP selection --- p.32 / Chapter 2.3.3. --- DNA sample preparation --- p.35 / Chapter 2.3.4. --- Genotyping methods --- p.36 / Chapter 2.3.4.1. --- Allele specific Tm shift assay --- p.36 / Chapter 2.3.4.2. --- Mass spectrometry assay --- p.40 / Chapter 2.4. --- Data quality control --- p.42 / Chapter 2.4.1. --- Stage 1 --- p.42 / Chapter 2.4.2. --- Stage 2 --- p.42 / Chapter 2.5. --- Statistical analysis --- p.45 / Chapter 2.5.1. --- Stage 1 analysis --- p.45 / Chapter 2.5.2. --- Stage 2 analysis --- p.45 / Chapter 2.5.3. --- Stage 1 and 2 combined analysis --- p.46 / Chapter CHAPTER 3. --- Results / Chapter 3.1. --- Clinical characteristics of subjects in stages 1 and 2 studies --- p.48 / Chapter 3.2. --- Case-control associations in stage 1 --- p.51 / Chapter 3.2.1. --- Association with T2D --- p.51 / Chapter 3.2.2. --- Association with T2D subset by metabolic syndrome --- p.54 / Chapter 3.3. --- Case-control associations in stage 2 --- p.60 / Chapter 3.3.1. --- SNP selection for genotyping --- p.60 / Chapter 3.3.2. --- Association with T2D --- p.63 / Chapter 3.3.3. --- Association with T2D subset by metabolic syndrome --- p.64 / Chapter 3.4. --- Case-control associations in combined stages 1 and 2 --- p.66 / Chapter 3.4.1. --- Association with T2D --- p.66 / Chapter 3.4.2. --- Association with T2D subset by metabolic syndrome --- p.70 / Chapter 3.4.3. --- Association with T2D subset by age at diagnosis --- p.74 / Chapter 3.4.4. --- Association with T2D subset by gender --- p.76 / Chapter 3.4.5. --- Genetic epistasis for T2D association --- p.79 / Chapter 3.5. --- Metabolic traits associations in control subjects in combined stages 1 and 2 studies --- p.83 / Chapter CHAPTER 4. --- Discussion --- p.86 / Chapter 4.1. --- Role of insulin secretion genes in type 2 diabetes --- p.87 / Chapter 4.2. --- Role of insulin action genes in type 2 diabetes --- p.92 / Chapter 4.3. --- Combined genetic effects on risk for type 2 diabetes --- p.97 / Chapter 4.4. --- Summary --- p.98 / Chapter 4.5. --- Limitation of this study and future direction --- p.101 / REFERENCES --- p.104 / APPENDICES --- p.119 / Chapter Appendix 1: --- Gene structure and linkage disequilibrium of genotyped SNPs of candidate genes --- p.119 / Chapter Appendix 2: --- Information of SNPs genotyped in stage 1 --- p.130 / Chapter Appendix 3: --- T2D association results (additive model) of 152 SNPs for stage 1 case- control samples --- p.137 / Chapter Appendix 4: --- T2D association results (additive model) of 152 SNPs for stage 1 case- control samples subset by metabolic syndrome status in cases --- p.144 / Chapter Appendix 5: --- T2D association results (additive model) of 22 SNPs for stage 2 case- control samples --- p.151 / Chapter Appendix 6: --- T2D association results (additive model) of 22 SNPs for stage 2 case- control samples subset by metabolic syndrome status in cases --- p.153

Lam Tsz Yan. / Thesis submitted in: October 2007. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2008. / Includes bibliographical references. / Abstracts in English and Chinese. / Abstract (English) --- p.i / 論文摘要 --- p.iv / Acknowledgements --- p.vi / Publications --- p.vii / Abbreviations --- p.ix / Contents --- p.x / Chapter 1. --- General Introduction --- p.1 / Chapter 1.1. --- Obesity --- p.1 / Chapter 1.1.1. --- Overview --- p.1 / Chapter 1.1.2. --- Pathophysiology --- p.1 / Chapter 1.1.3. --- Central obesity --- p.3 / Chapter 1.2. --- Diabetes --- p.7 / Chapter 1.2.1. --- Overview --- p.7 / Chapter 1.2.2. --- Pathophysiology --- p.8 / Chapter 1.3. --- Lipolysis --- p.9 / Chapter 1.3.1. --- Proteins participating in triglyceride lipolysis --- p.10 / Chapter 1.3.1.1. --- Hormone-sensitive lipase (HSL) --- p.10 / Chapter 1.3.1.2. --- Adipose triglyceride lipase (ATGL) --- p.10 / Chapter 1.3.1.3. --- Perilipins --- p.11 / Chapter 1.3.2. --- Abnormal regulation of lipolysis in obesity --- p.11 / Chapter 1.3.3. --- Disturbed lipolysis in insulin resistance --- p.13 / Chapter 1.4. --- Pharmacotherapy --- p.13 / Chapter 1.4.1. --- Obesity --- p.13 / Chapter 1.4.1.1. --- Orlistat --- p.13 / Chapter 1.4.1.2. --- Sibutramine --- p.14 / Chapter 1.4.1.3. --- Others --- p.15 / Chapter 1.4.2. --- Diabetes --- p.15 / Chapter 1.4.2.1. --- Modulation of the β-cells functions --- p.15 / Chapter 1.4.2.2. --- Control of glucose output --- p.16 / Chapter 1.4.2.3. --- Modulation of carbohydrate absorption --- p.16 / Chapter 1.4.2.4. --- Thiazolidinediones (TZDs) --- p.16 / Chapter 1.5. --- Animal models used in type 2 diabetes and obesity research --- p.17 / Chapter 1.6. --- Aim of study --- p.18 / Chapter 2. --- β-Adrenoceptors (β-ARs) --- p.21 / Chapter 2.1. --- Introduction --- p.21 / Chapter 2.1.1. --- Hormonal control of lipolysis --- p.21 / Chapter 2.1.1.1. --- Catecholamines --- p.21 / Chapter 2.1.1.2. --- Insulin --- p.23 / Chapter 2.1.2. --- Folic acid (folate) --- p.23 / Chapter 2.1.2.1. --- Physiological roles of folate --- p.23 / Chapter 2.1.2.2. --- Folate deficiency and its consequences --- p.24 / Chapter 2.1.2.3. --- Hyperhomocysteinemia --- p.24 / Chapter 2.1.2.4. --- Pleiotropic effects of folate --- p.25 / Chapter 2.1.2.5. --- Role of folate in type 2 diabetes and obesity --- p.26 / Chapter 2.1.3. --- Lingzhi --- p.28 / Chapter 2.1.3.1. --- Triterpenoids --- p.29 / Chapter 2.1.3.2. --- Polysaccharides --- p.30 / Chapter 2.2. --- Materials and methods --- p.32 / Chapter 2.2.1. --- Materials --- p.32 / Chapter 2.2.1.1. --- Composition of physiological salt solution --- p.32 / Chapter 2.2.1.2. --- Materials used in lipolysis experiment --- p.32 / Chapter 2.2.1.3. --- Materials used in reverse transcription polymerase chain reaction (RT-PCR) --- p.34 / Chapter 2.2.1.4. --- Materials used in Western blotting --- p.34 / Chapter 2.2.2. --- Methods --- p.36 / Chapter 2.2.2.1. --- Lipolysis experiment --- p.36 / Chapter 2.2.2.1.1. --- Animals --- p.36 / Chapter 2.2.2.1.2. --- Drug administration --- p.36 / Chapter 2.2.2.1.3. --- Isolation of adipocytes --- p.37 / Chapter 2.2.2.1.4. --- Lipolysis measurement --- p.37 / Chapter 2.2.2.1.5. --- Data analysis --- p.38 / Chapter 2.2.2.2. --- RT-PCR --- p.38 / Chapter 2.2.2.2.1. --- Tissue preparation --- p.39 / Chapter 2.2.2.2.2. --- RNA extraction --- p.39 / Chapter 2.2.2.2.3. --- Reverse transcription (RT) --- p.40 / Chapter 2.2.2.2.4. --- Polymerase chain reaction (PCR) --- p.40 / Chapter 2.2.2.2.5. --- Agarose gel electrophoresis --- p.41 / Chapter 2.2.2.2.6. --- Data representation and analysis --- p.41 / Chapter 2.2.2.3. --- Western blotting --- p.42 / Chapter 2.2.2.3.1. --- Tissue preparation --- p.42 / Chapter 2.2.2.3.2. --- Protein extraction --- p.42 / Chapter 2.2.2.3.3. --- Western blotting --- p.42 / Chapter 2.2.2.3.4. --- Data representation and analysis --- p.43 / Chapter 2.3. --- Results --- p.43 / Chapter 2.3.1. --- Studies on the β-adrenoceptor-mediated lipolytic response in +m/+db and +db/+db mice --- p.43 / Chapter 2.3.1.1. --- Effect of β2-adrenoceptor agonist on lipolysis --- p.43 / Chapter 2.3.1.2. --- Effect of β3-adrenoceptor agonists and their antagonists on lipolysis --- p.44 / Chapter 2.3.1.3. --- Effect of non-selective β-adrenoceptor agonists and their antagonists on lipolysis --- p.45 / Chapter 2.3.1.4. --- Effect of modulators of intracellular cyclic nucleotide monophosphate on lipolysis --- p.46 / Chapter 2.3.1.5. --- Effect of exogenously delivered nitric oxide on lipolysis --- p.47 / Chapter 2.3.1.6. --- Gene expression of β-adrenoceptors in white adipose tissue --- p.47 / Chapter 2.3.1.7. --- Protein expression of β-adrenoceptors in white adipose tissue --- p.47 / Chapter 2.3.2. --- Effect of folic acid treatment on lipolysis --- p.48 / Chapter 2.3.2.1. --- Determination of body weight --- p.48 / Chapter 2.3.2.2. --- Effect of β2-adrenoceptor agonist on lipolysis --- p.48 / Chapter 2.3.2.3. --- Effect of β-adrenoceptor agonists on lipolysis --- p.49 / Chapter 2.3.2.4. --- Effect of non-selective β-adrenoceptor agonist on lipolysis --- p.50 / Chapter 2.3.2.5. --- Effect of modulators of intracellular cyclic nucleotide monophosphate on lipolysis --- p.51 / Chapter 2.3.2.6. --- Effect of exogenously delivered nitric oxide on lipolysis --- p.52 / Chapter 2.3.2.7. --- Gene expression of β-adrenoceptors in white adipose tissue --- p.52 / Chapter 2.3.2.8. --- Protein expression of β-adrenoceptors in white adipose tissue --- p.53 / Chapter 2.3.3. --- Effect of Lingzhi (water-extract) treatment on lipolysis --- p.54 / Chapter 2.3.3.1. --- Determination of body weight --- p.54 / Chapter 2.3.3.2. --- Lipolytic effect of forskolin --- p.54 / Chapter 3. --- Peroxisome Proliferator-Activated Receptor-y (PPAR-γ) --- p.91 / Chapter 3.1. --- Introduction --- p.91 / Chapter 3.1.1. --- Peroxisome proliferator-activated receptors --- p.91 / Chapter 3.1.1.1. --- Peroxisome proliferator-activated receptor-γ --- p.91 / Chapter 3.1.1.1.1. --- "PPAR-γ in obesity, lipid metabolism and type 2 diabetes" --- p.91 / Chapter 3.1.1.1.2. --- PPAR-γ in inflammation and atherosclerosis --- p.92 / Chapter 3.1.1.2. --- PPAR-γ and thiazolidinediones --- p.93 / Chapter 3.2. --- Materials and method --- p.95 / Chapter 3.2.1. --- Materials --- p.95 / Chapter 3.2.1.1. --- Composition of physiological salt solution --- p.95 / Chapter 3.2.1.2. --- Materials used in lipolysis experiment --- p.95 / Chapter 3.2.1.3. --- Materials used in RT-PCR --- p.95 / Chapter 3.2.1.4. --- Materials used in Western blotting --- p.95 / Chapter 3.2.2. --- Methods --- p.96 / Chapter 3.2.2.1. --- Lipolysis experiment --- p.96 / Chapter 3.2.2.2. --- RT-PCR --- p.96 / Chapter 3.2.2.3. --- Western blotting --- p.97 / Chapter 3.3. --- Results --- p.97 / Chapter 3.3.1. --- Effect of PPAR-γ agonists on lipolysis --- p.97 / Chapter 3.3.2. --- Gene expression of PPAR-γ in white adipose tissue --- p.97 / Chapter 3.3.3. --- Protein expression of PPAR-γ in white adipose tissue --- p.97 / Chapter 4. --- 3-Hydoxy-3-MethylgIutaryl Coenzyme A (HMG-CoA) Reductase --- p.106 / Chapter 4.1. --- Introduction --- p.106 / Chapter 4.1.1. --- Cholesterol metabolism and cardiovascular diseases --- p.106 / Chapter 4.1.2. --- Statins --- p.106 / Chapter 4.1.2.1. --- Modes of action --- p.107 / Chapter 4.1.2.2. --- Therapeutic efficacy of statins --- p.108 / Chapter 4.1.2.2.1. --- Diabetes --- p.108 / Chapter 4.1.2.2.2. --- Coronary artery disease --- p.109 / Chapter 4.1.3. --- Distribution and expression of HMG-CoA reductase --- p.109 / Chapter 4.2. --- Materials and method --- p.110 / Chapter 4.2.1. --- Materials --- p.110 / Chapter 4.2.1.1. --- Composition of physiological salt solution --- p.110 / Chapter 4.2.1.2. --- Materials used in lipolysis experiment --- p.110 / Chapter 4.2.1.3. --- Materials used in RT-PCR --- p.110 / Chapter 4.2.1.4. --- Materials used in Western blotting --- p.110 / Chapter 4.2.2. --- Methods --- p.110 / Chapter 4.2.2.1. --- Lipolysis experiment --- p.110 / Chapter 4.2.2.2. --- RT-PCR --- p.111 / Chapter 4.2.2.3. --- Western blotting --- p.111 / Chapter 4.3. --- Results --- p.112 / Chapter 4.3.1. --- Effect of statins on lipolysis --- p.112 / Chapter 4.3.2. --- Gene expression of HMG-CoA reductase in various internal organs --- p.112 / Chapter 4.3.3. --- Protein expression of HMG-CoA reductase in various internal organs --- p.113 / Chapter 5. --- Discussion --- p.122 / Chapter 5.1. --- β-adrenoceptor-mediated lipolysis --- p.122 / Chapter 5.2. --- Studies on peroxisome proliferator-activated receptor-γ --- p.140 / Chapter 5.3. --- Studies on HMG-CoA reductase --- p.142 / Chapter 5.4. --- Further studies --- p.147 / Chapter 5.5. --- Conclusions --- p.148 / Chapter 6. --- References --- p.152

No description available.

The aim of the present study was to investigate the influence of insulin-dependent diabetes mellitus (IDDM) on the cognitive functioning, learning difficulties, and behavioral problems in children between the ages of 7 and 12. The sample was composed of elementary school children living in Ankara, Turkey. Data was collected by administering demographic information form, Children&rsquo / s Depression Inventory (CDI), Strength and Difficulties Questionnaire (SDQ), Wechsler Intelligence Scale for Children&ndash / Revised (WISC-R), and Specific Learning Disability Scale. One-way ANOVAs were employed to examine the differences among the levels of parental education, income, school achievement, and child&rsquo / s adherence to IDDM in terms of WISC-R scores, learning difficulty related variables, behavioral problems, and depression. Results revealed that children with low adherence to IDDM were more likely to experience behavioral problems and depression. T-tests were conducted to examine the mean differences between IDDM and control groups in terms of WISC-R scores, and the variables related to learning difficulties, behavioral problems, and depression. As compared to control group, children with IDDM had lower WISC-R information, similarities, arithmetic, and total scores. Also, children with IDDM had lower achievement in several arithmetic, reading, and writing tasks. Furthermore, hierarchical multiple regression analyses were conducted to test the effect of IDDM adherence, age of onset, and illness duration on cognitive functioning, learning, and behaviors. The results did not reveal any significant effect of IDDM related variables on children&rsquo / s cognitive functioning, learning, or behaviors. Findings were discussed with reference to the relevant literature. Implications of the study were discussed and future research topics were suggested.

Thesis (Ph. D.)--University of Missouri--Columbia, 2001. / Typescript. Vita. Includes bibliographical references (leaves 228-243). Also available on the Internet.

Medicinal plants, as part of traditional ingestion practices, may contain antioxidants to combat the oxidative stress which is implicated in prediabetes as well as many of the complications of diabetes, As Indigenous Peoples move further from their traditional lifestyles, and therefore their use of medicinal plants, incidence of diabetes has increased dramatically, Those medicinal plants of the boreal forest that have been used for 3 or more symptoms of diabetes or its complications were selected for analysis. Three different assays (DPPH, NBT/xanthine oxidase and DCF/APPH) determined the antioxidant activity of 35 medicinal plant species. The majority of the species (89%) had free radical scavenging activity significantly greater than the market produce tested (Tukey, P < 0.05), 63% had superoxide scavenging activities similar to vitamin C, and eight species had free radical scavenging activity similar to green tea. Considering that many of these species are also used for food or beverage they represent an antioxidant benefit to the traditional lifestyle. Among the parts used medicinally, roots and barks were used the most frequently with activity in the order of fruit > bark > leaves > roots. The perennials selected had activity in rank trees > shrubs > herbs and the activity associated with habitat found rocky areas > woodland > wet/boggy habitats. Species used for symptoms such as diarrhea, rheumatism, tonic and heart/chest pain were typically high in antioxidant activity. Using cluster analysis it was determined that species used for diarrhea and heart disease as well as those used for a combination of tonic, sores, urinary, blood, pregnancy and boils could also be species with high antioxidant activity. The greater the number of symptoms a species was used for, the greater the activity. Three species with high antioxidant activities, Rhus hirta, Cornus stolonifera and Solidago canadensis, inhibited TNF production in human macrophage cells suggesting a po